Sandoz 2nd Biosimilar At FDA; Seeks Slice Of Enbrel Sales
This article was originally published in Scrip
Executive Summary
With the FDA's acceptance of its 351(k) application, Novartis unit Sandoz has moved closer to gaining the agency's approval to market a second biosimilar – this time, a version of Amgen's tumor necrosis factor alpha (TNF-alpha) inhibitor Enbrel (etanercept), which reported $9bn in global sales in 2014, with close to half of that coming from the U.S.